Natriuretic Hormones

Seldin and Geibisch's The Kidney

Volumn 1, Issue , 2013, Pages 1241-1281

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879676087     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381462-3.00037-9     Document Type: Chapter

References (442)

1. Abassi Z.A., Powell J.R., Golomb E., Keiser H.R. Renal and systemic effects of urodilatin in rats with high-output heart failure. Am J Physiol 1992, 262:F615-F621.
2. Abell T.J., Richards A.M., Ikram H., Espiner E.A., Yandle T. Atrial natriuretic factor inhibits proliferation of vascular smooth muscle cells stimulated by platelet derived growth factor. Biochem Biophys Res Commun 1989, 160:1392-1396.
3. Abraham W.T., Lowes B.D., Ferguson D.A., Odom J., Kim J.K., Robertson A.D., et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998, 4:37-44.
4. Ackerman B.H., Overton R.M., McCormick M.T., Schocken D.D., Vesely D.L. Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. J Pharmacol Exp Therap 1997, 282:603-608.
5. Ackermann U., Irizawa T.G., Milojevie S., Sonnennberg H. Cardiovascular effects of atrial extracts in anesthetized rats. Can J Physiol Pharmacol 1984, 62:819-826.
6. Agmon Y., Peleg H., Greenfeld Z., Rosen S., Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994, 94:1069-1075.
7. Allgren R.L., Marbury T.C., Rahman S.N., Weisberg L.S., Fenves A.Z., Lafayette R.A., et al. Anaritide in acute tubular necrosis. N Engl J Med 1997, 336:828-834.
8. Anderson J.V., Donckier J., Payne N.N., Beacham H., Stater J.D.H., Bloom S.R. Atrial natriuretic peptide: evidence as a natriuretic hormone at physiological plasma concentrations in man. Clin Sci 1987, 72:305-312.
9. Anderson R.J., Schrier R.W. Acute renal failure. Diseases of the Kidney and Urinary Tract 2001, 1093-1136. Lippincott, Williams & Wilkins, Philadelphia. 7th ed. R.W. Schrier (Ed.).
10. Appel R.G. Growth inhibitory activity of atrial natriuretic factor in rat glomerular mesangial cells. FEBS Lett 1988, 238:135-138.
11. Appel R.G. Growth-regulatory properties of atrial natriuretic factor. Am J Physiol 1992, 262:F911-F918.
12. Arendt R., Gerbes A., Ritter D., Stangl E., Bach P., Zahringer J. Atrial natriuretic factors in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver. J Hypertens 1986, 4(Suppl. 2):131-135.
13. Argentin S., Drouin J., Nemer M. Thyroid hormone stimulates rat pro-natriodilatin mRNA levels in primary cardiocyte cultures. Biochem Biophys Res Commun 1987, 146:1336-1341.
14. Atarashi K., Mulrow P.J., Franco-Saenz R., Snajdar R., Rapp J. Inhibition of aldosterone production by an atrial extract. Science 1984, 224:992-994.
15. Atlas S.A., Kleinert H.D., Camargo M.J., Januszewicz A., Sealey J.E., Laragh J.H., et al. Purification, sequencing and synthesis of natriuretic and vasoactive rat atrial peptide. Nature 1984, 309:717-719.
16. Baeyens D.A., Price E., Winters C.J., Vesely D.L. Diving increases atrial natriuretic factor-like peptide in fresh water diving turtles. Comp Physiol Biochem 1989, 94 A:515-518.
17. Baeyens D.A., Walters J.M., Vesely D.L. Atrial natriuretic factor increases the magnitude of duodenal spontaneous phasic contractions. Biochem Biophys Res Commun 1988, 155:1437-1443.
18. Baker B.J., Wu W.L., Winters C.J., Dinh H., Wyeth R., Sallman A.L., et al. Exercise increases the circulating concentration of the N-terminus of the atrial natriuretic factor prohormone in normal humans. Am Heart J 1991, 122:1395-1402.
19. Ballerman B.J., Bloch K.D., Seidman J.G., Brenner B.M. Atrial natriuretic peptide transcription, secretion and glomerular receptor activity during mineralocorticoid escape in the rat. J Clin Invest 1986, 78:840-843.
20. Banting F.G., Best C.H. The internal secretion of the pancreas. J Lab Clin Med 1922, 7:251-261.
21. Barletta G., Lazzeri C., Vecchiarino S., Del Bene R., Messeri G., Dello Sbarba A., et al. Low-dose C-type natriuretic peptide does not affect cardiac and renal function in humans. Hypertension 1988, 31:802-808.
22. Barr C.S., Rhodes P., Struthers A.D. C-type natriuretic peptide. Peptides 1996, 17:1243-1251.
23. Beltowski J., Wojcicka G. Regulation of renal tubular transport by cardiac natriuretic peptides: two decades of research. Med Sci Monit 2002, 8:RA39-RA52.
24. Benjamin B.A., Peterson T.V. Effects of proANF-(31-67) on sodium excretion in conscious monkeys. Am J Physiol Regul Integr Comp Physiol 1995, 269:R1351-R1355.
25. Benoist C., Chambon P. In vivo sequence requirements of the SV40 early promoter region. Nature 1981, 290:304-310.
26. Bhalla S.S., Robitaille L., Nemer M. Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter. J Biol Chem 2001, 276:11439-11445.
27. Bloch K.D., Scott J.A., Zisfein J.B., Fallon J.T., Margolis N.N., Seidman C.E., et al. Biosynthesis and secretion of proatrial natriuretic factor by cultured rat cardiocytes. Science 1985, 230:1168-1171.
28. Bompiani G.D., Rouiller C.H., Hatt P.Y. Le tissue de conduction du coeur chez le rat. Etude au microscope electronique. I. Le tronc commun du faisceau de His et les cellules claires de L'oreillette droite. Arch Mal Coeur 1959, 52:1257-1274.
29. Borst J.G.G. The maintenance of an adequate cardiac output by the regulation of the urinary excretion of water and sodium chloride; an essential factor in the genesis of edema. Acta Med Scand 1948, 130(Suppl. 207):1-71.
30. Bovy P.R., O'Neal J.M., Olins G.M., Patton D.R., Mehta P.P., McMahon E.G., et al. A synthetic linear decapeptide binds to the atrial natriuretic peptide receptors and demonstrates cyclase activation and vasorelaxant activity. J Biol Chem 1989, 264:20309-20313.
31. Brady H.R., Brenner B.M., Clarkson M.R., Lieberthal W. Acute renal failure. Brenner & Rector's the kidney 2000, 1201-1262. WB Saunders, Philadelphia. 6th ed. M. Brenner (Ed.).
32. Brandt R.B., Redfield M.M., Aarhus L.L., Lewicki J.A., Burnett J.C. Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol 1994, 266:R936-R943.
33. Breathnach R., Chambon P. Organization and expression of eukaryotic split genes coding for proteins. Am Rev Biochem 1981, 50:349-383.
34. Brenner B.M., Ballermann B.J., Gunning M.E., Zeidel M.L. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990, 70:665-699.
35. Brenner R.M., Chertow G.M. The rise and fall of atrial natriuretic peptide for acute renal failure. Curr Opin Nephrol Hypertens 1997, 6:474-476.
36. Brezis M., Rosen S., Silva P., Epstein F.H. Renal ischemia: a new perspective. Kidney Int 1984, 26:375-383.
37. Bricker N.S., Klahr S., Purkerson M., Schultze R.G., Avioli L.V., Binge S.J. In vitro assay for a humoral substance present during volume expansion and uremia. Nature 1968, 219:1058-1059.
38. Buckley M.G., Sethi D., Markandu N.D., Sagnella G.A., Singer D.R., MacGregor G.A. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci 1992, 83:437-444.
39. Burnett J.C., Granger J.P., Opgenorth T.J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984, 247:F863-F866.
40. Carrithers S.L., Ott C.E., Hill M.J., Johnson B.R., Cai W., Chang J.J., et al. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int 2004, 65:40-53.
41. Carrithers S.L., Hill M.J., Johnson B.R., O'Hara S.M., Jackson B.A., Ott C.E., et al. Renal effects of uroguanylin and guanylin in vivo. Braz J Med Biol Res 1999, 32:1137-1144.
42. Casey K.F., Machiedo G.W., Lyons M.J., Slotman G.J., Novak R.T. Alteration of postischemic renal pathology by prostaglandin infusion. J Surg Res 1980, 29:1-10.
43. Cataliotti A., Malatino L.S., Jougasaki M., Zoccali C., Castellino P., Giacone G., et al. Circulating natriuretic peptide concentrations in patients with end-state renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001, 76:1111-1119.
44. Charron F., Paradis P., Bronchain O., Nemer G., Nemer M. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression. Mol Cell Biol 1999, 19:4355-4365.
45. +-ATPase by atrial natriuretic factor in rat renal medullary thick ascending limb of Henle's loop. Cell Biochem Funct 1990, 8:25-29.
46. Chartier L., Schiffrin E., Thibault G. Effect of atrial natriuretic factor (ANF)-related peptides on aldosterone secretion by adrenal glomerulosa cells: critical role of the intramolecular disulphide bond. Biochem Biophys Res Commun 1984, 122:171-174.
47. Chauhan S.D., Nilsson H., Ahluwalia A., Hobbs A.J. Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003, 100:1426-1431.
48. Chen J.H., Tsai J.H., Lai Y.H., Hwang S.J. Plasma atrial natriuretic peptide in patients with chronic renal failure. J Formos Med Assoc 1990, 89:645-650.
49. Chen X.W., Ying W.Z., Valentin J.P., Ling K.T., Lin S.Y., Wiedemann E., et al. Mechanism of the natriuretic action of γ-melanocyte-stimulating hormone. Am J Physiol 1997, 272:R1946-R1953.
50. Chinkers M., Garbers D.L., Chang M.S., Lowe D.G., Chin H.M., Goeddel D.V., et al. A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor. Nature 1989, 338:78-83.
51. +-ATPase of the atrial natriuretic peptides. Endocrinology 1995, 136:2033-2039.
52. Christoffensen C., Goetz J.P., Bartles E.D., Larsen M.D., Ribel U., Rehfeld J.F., et al. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 2002, 40:54-60.
53. Chun T.H., Itoh H., Ogawa Y., Tamura N., Takaya K., Igaki T., et al. Shear stress augments expression of C-type natriuretic peptide and adrenomedullin. Hypertension 1997, 29:1296-1302.
54. Clark L.C., Farghaly H., Saba S.R., Vesely D.L. Amelioration with vessel dilator of acute tubular necrosis and renal failure established for 2 days. Am J Physiol 2000, 278:H1555-H1564.
55. Clavell A.L., Stingo A.J., Wei C.M., Heublein D.M., Burnett J.C. C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol 1993, 264:R290-R295.
56. Cody R.J., Atlas S.A., Laragh J.H., Kubo S.H., Covit A.B., Ryman K.S., et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362-1374.
57. Conger J.D., Falk S.A., Yuan B.H., Schrier R.W. Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int 1989, 35:1126-1132.
58. Corboy J.C., Walker R.J., Simmonds M.B., Wilkins G.T., Richards A.M., Espiner E.A. Plasma natriuretic peptides and cardiac volume during acute changes in intravascular volume in haemodialysis patients. Clin Sci 1994, 87:679-684.
59. Cousins K.L., Farrell A.P., Sweeting R.M., Vesely D.L., Keen J.E. Release of atrial natriuretic factor prohormone peptides 1-30, 31-67, and 99-126 from fresh-water and sea-water acclimated perfused trout (Oncorhynchus mykiss) hearts. J Exp Biol 1997, 200:1351-1362.
60. Crawford I., Maloney P.C., Zeitlin P.L., Guggino W.B., Hyde S.C., Turley H., et al. Immunocytochemical localization of the cystic fibrosis gene product CFTR. Proc Natl Acad Sci USA 1991, 88:9262-9266.
61. Crews C.M., Alessandrini A., Erikson R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992, 258:478-480.
62. Currie M.G., Fok K.F., Kato J., Moore R.J., Hamra F.K., Duffin K.L., et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc Natl Acad Sci USA 1992, 89:947-951.
63. Currie M.G., Geller D.M., Cole B.R., Boylan J.G., Yu Sheng W, Holmberg S.W., et al. Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. Science 1983, 221:71-73.
64. Currie M.G., Geller D.M., Cole B.R., Siegel N.R., Fox K.F., Adams S.P., et al. Purification and sequence analysis of bioactive atrial peptides. Science 1984, 223:67-69.
65. Dagnino L., Lavigne J.P., Nemer M. Increased transcripts for B-type natriuretic peptide in spontaneously hypertensive rats: quantitative polymerase chain reaction for atrial and brain natriuretic peptide transcripts. Hypertension 1992, 20:690-700.
66. Davidman M., Olson P., Kohen J., Leither T., Kjellstrand C. Iatrogenic renal disease. Arch Intern Med 1991, 151:1809-1812.
67. Davis R.J. Signal transduction by the JNK group of Map kinases. Cell 2000, 103:239-252.
68. Debold A.J. Heart atria granularity effects changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979, 161:508-511.
69. Debold A.J., Borenstein H.B., Veress A.T., Sonnenberg H. A rapid and potent natriuretic response to intravenous injections of atrial myocardial extracts in rats. Life Sci 1981, 28:89-94.
70. DeBold A.J., Salerno T.A. Natriuretic activity of extracts obtained from hearts of different species and from various rat tissues. Can J Physiol Pharmacol 1983, 61:127-130.
71. De Lean A., Gutkowska J., McNicoll N., Schiller P.W., Cantin M., Genest J. Characterization of specific recepors for atrial natriuretic factor in bovine adrenal zona glomerulosa. Life Sci 1984, 35:2311-2318.
72. De Palo E.F., Woloszczuk W., Meneghetti M., DePalo C.B., Nielsen H.B., Secher N.H. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000, 46:843-847.
73. de Wardener H.E., Mills I.H., Clapham W.F., Hayter C.J. Studies on the efferent mechanism of sodium diuresis which follows administration of intravenous saline in the dog. Clin Sci 1961, 21:249-258.
74. Dietz J.R. Release of natriuretic factor from rat heart-lung preparation by atrial distension. Am J Physiol 1984, 247:R1093-R1096.
75. Dietz J.R., Landon C.S., Nazian S.J., Vesely D.L., Gower W.R. Effects of cardiac hormones on arterial pressure and sodium excretion in NPRa knockout mice. Exp Biol Med 2004, 229:813-818.
76. Dietz J.R., Nazian S.J., Vesely D.L. Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distention. Am J Physiol 1991, 260:H1774-H1778.
77. Dietz J.R., Scott D.Y., Landon C.S., Nazian S.J. Evidence supporting a physiological role for pro ANP (1-30) in the regulation of renal excretion. Am J Physiol 2001, 280:R1510-R1517.
78. Dietz J.R., Vesely D.L., Gower W.R., Nazian S.J. Secretion and renal effects of ANF prohormone peptides. Clin Exp Pharmacol Physiol 1995, 22:115-120.
79. Dietz J.R., Vesely D.L., Gower W.R., Landon C.S., Lee S., Nazian S.J. Neutralization of proANP 1-30 exacerbates hypertension in spontaneously hypertensive rat (SHR). Clin Exp Pharm Physiol 2003, 30:627-631.
80. Dietz J.R., Vesely D.L., Nazian S.J. The effect of changes in sodium intake on atrial natriuretic factor (ANF) and peptides derived from the N-terminus of the ANF prohormone in the rat. Proc Soc Exp Biol Med 1992, 200:44-48.
81. Dillingham M.A., Anderson R.J. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986, 250:F963-F966.
82. Drewett J.G., Garbers D.L. The family of guanylyl cyclase receptors and their ligands. Endocr Rev 1994, 15:135-162.
83. Edwards B.S., Ackerman D.M., Lee M.E., Reeder G.S., Wold L.E., Burnett J.C. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest 1988, 81:82-86.
84. Ehrenreich H., Sinowatz R., Schulz R.M., Arendt R.M., Goebel F.D. Immunoreactive atrial natriuretic peptide (ANP) in endoscopic biopsies of human gastrointestinal tract. Res Exp Med 1989, 189:421-425.
85. Eichelbaum E.J., Vesely B.A., Alli A.A., Sun Y., Gower W.R., Vesely D.L. Four cardiac hormones decrease up to 82% of human medullary thyroid carcinoma cells within 24 hours. Endocrine 2006, 30:325-332.
86. Eichelbaum E.J., Sun Y., Alli A.A., Gower W.R., Vesely D.L. Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 2008, 38:562-570.
87. Elitsur N., Lorenz J.N., Hawkins J.A., Rudolph J.A., Witte D., Yang L.E., et al. The proximal convoluted tubule is a target for the uroguanylin-regulated natriuretic response. J Pediatr Gastroenterol Nutr 2006, 43:S74-S81.
88. Elsner D., Muders F., Muntze A., Kromer E.P., Forssmann W.G., Riegger G. Efficacy of prolonged infusion of urodilatin [ANP 95-126] in patients with congestive heart failure. Am Heart J 1995, 129:766-773.
89. Entzeroth M., Doods H.N., Wieland H.A., Wiene W. Adrenomedullin mediates vasodilation via CGRP1 receptors. Life Sci 1995, 56:PL19-PL25.
90. Eto T., Washimine H., Kato J., Kitamura K., Yamamoto Y. Adrenomedullin and proadrenalmedullin N-terminal 20 peptide in impaired renal function. Kidney Int Suppl 1996, 55:S148-S149.
91. Fan X., Hamra F.K., Freeman R.H., Eber S.L., Krause W.J., Lin R.W., et al. Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Biochem Biophys Res Commun 1996, 219:457-462.
92. Fink M.P., Mac Vittie T.J., Casey L.C. Effects of nonsteroidal anti-inflammatory drugs on renal function in septic dogs. J Surg Res 1984, 36:516-525.
93. Flynn T.G. Past and current perspectives on the natriuretic peptides. Proc Soc Exp Biol Med 1996, 213(2):98-104.
94. Flynn T.G., deBold M.L., deBold A.J. The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties. Biochem Biophys Res Commun 1983, 117:859-865.
95. Fonteles M.C., Greenberg R.N., Monteiro H.A.S., Currie M.G., Forte L.R. Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. Am J Physiol 1998, 44:F191-F197.
96. Fonteles M.C., Carrithers S.L., Monteiro H.S.A., Carvalho A.F., Coelho G.R., Greenberg R.N., et al. Renal effects of serine-7 analog of lymphoguanylin in ex vivo rat kidney. Am J Physiol Renal Physio 2001, 280:F207-F213.
97. Forte L.R. Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Biochem Biophys Res Commun 1996, 219:457-462.
98. Forte L.R., Eber S.L., Fan X., London R.M., Rowland L.M., Chin D.T., et al. Lymphoguanylin: cloning characterization of a unique member of the guanylin peptide family. Endocrinology 1999, 140:1800-1806.
99. Forte L.R., Fan S., Hamra F.K. Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Am J Kidney Dis 1996, 28:296-304.
100. Forte L.R., Krause W.J., Freeman R.H. Escherichia coli enterotoxin receptors: localization in opossum kidney, intestine, and testis. Am J Physiol 1989, 257:F874-F881.
101. Forte L.R., London R.M., Freeman R.H., Krause W.J. Guanylin peptides: renal actions mediated by cyclic GMP. Am J Physiol Renal Physiol 2000, 278:F180-F191.
102. Franz M., Woloszczuk W., Horl W.H. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000, 58:374-378.
103. Franz M., Woloszczuk W., Horl W.H. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001, 59:1928-1934.
104. Freeman R.H., David J.O., Vari R.C. Renal response to atrial natriuretic factor in conscious dogs with caval constriction. Am J Physiol 1985, 248:R495-R500.
105. Freid T.A., Osgood R.W., Stein J.H. Tubular site(s) of action of atrial natriuretic peptide in rat. Am J Physiol 1988, 255:F313-F316.
106. Fukae H., Kinoshita H., Fujimoto S., Kita T., Nakazato M., Eto T. Changes in urinary levels and renal expression of uroguanylin on low or high salt diets in rats. Nephron 2002, 92:373-378.
107. Fukioka S., Tamaki T., Fukui K., Ikahara T., Abe Y. Effects of a synthetic human atrial natriuretic polypeptide on regional blood flow in rats. Eur J Pharmacol 1985, 109:301-304.
108. Fyhrquist F., Tikkanen I., Totterman K.J., Hynynen M., Tikkanen T., Andersson S. Plasma atrial natriuretic peptide in health and disease. Eur Heart J 1987, 8(Suppl. B):117-122.
109. Garcia N.H., Garvin J.L. ANF and angiotensin II interact via kinases in the proximal straight tubule. Am J Physiol 1995, 268:F730-F735.
110. Garcia R., Cantin M., Thibault G., Ong H., Genest J. Relationship of specific granules to the natriuretic and diuretic activity of rat atria. Experientia 1982, 38:1071-1073.
111. Garcia R., Thibault G., Cantin M., Genest J. Effect of a purified atrial natriuretic factor on rat and rabbit vascular strips and vascular beds. Am J Physiol 1984, 247:R34-R39.
112. Garcia R., Thibault G., Nutt R.F., Cantin M., Genest J. Comparative vasoactive effects of native and synthetic atrial natriuretic factor (ANF). Biochem Biophys Res Commun 1984, 119:685-688.
113. Gardner D.G. Natriuretic peptides: markers or modulators of cardiac hypertrophy. Trends Endo Metab 2003, 14:411-416.
114. Gardner D.G., Deschepper C.T., Ganong W.F., Hane S., Fiddes J., Baxter J.D., et al. Extra-atrial expression of the gene for atrial natriuretic factor. Proc Natl Acad Sci USA 1986, 83:6697-6701.
115. Gardner D.G., Gertz B.J., Deschepper C.F., Kim D.Y. Gene for the rat atrial natriuretic peptide is regulated by glucocorticoids in vitro. J Clin Invest 1988, 82:1275-1281.
116. Gardner D.G., Kovacic-Milivojevic B.K., Garmai M. Molecular biology of the natriuretic peptides. Atrial natriuretic peptides 1997, 15-38. Research Signpost, Trivandrum, India. D.L. Vesely (Ed.).
117. Gauer O.H., Henry J.P., Seiker H.O. Cardiac receptors and fluid volume control. Progr Cardiovasc Dis 1961, 4:1-26.
118. Gauer O.H., Henry J.P. Circulatory basis of fluid volume control. Physiol Rev 1963, 43:423-481.
119. Geller D.M., Currie M.G., Siegel N.R., Fok K.F., Adams S.P., Needleman P. The sequence of an atriopeptigen: a precursor of the bioactive atrial peptides. Biochem Biophys Res Commun 1984, 121:802-807.
120. Geller D.M., Currie M.G., Wakitani K., Cole B.R., Adams S.P., Fok K.F., et al. Atriopeptins: a family of potent biologically active peptides derived from mammalian atria. Biochem Biophys Res Commun 1984, 120:333-338.
121. Gillespie D.J., Sandberg R.L., Koike T.I. Dual effect of left atrial receptors on the excretion of sodium and water in the dog. Am J Physiol 1973, 255:706-710.
122. Godellas C.V., Gower W.R., Fabri P.J., Knierim T.H., Giordano A.T., Vesely D.L. Atrial natriuretic factor (ANF) - a possible new gastrointestinal regulatory peptide. Surgery 1991, 110:1022-1027.
123. Goetz K.L., Bond G.C., Bloxham D.D. Atrial receptors and renal function. Physiol Rev 1975, 55:157-205.
124. Goodfriend T.L., Elliott M.E., Atlas S.A. Actions of synthetic atrial natriuretic factor on bovine adrenal glomerulosa. Life Sci 1984, 35:1675-1682.
125. Gomez-Sanchez E.P., Foecking M.F., Sellers D., Blankenship M.S., Gomez-Sanchez C.E. Is circulating ouabain-like compound quabain?. Am J Hypertens 1994, 7:647-650.
126. Gower W.R., Chiou S., Skolnick K., Vesely D.L. Molecular forms of circulating atrial natriuretic peptides in human plasma and their metabolites. Peptides 1994, 15:861-867.
127. Gower W.R., Dietz J.R., McCuen R.W., Fabri P.J., Lerner E.A., Schubert M.L. Regulation of atrial natriuretic peptide secretion by cholinergic and PACAP neurons of the gastric antrum. Am J Physiol 2003, 284:G68-G74.
128. Gower W.R., Dietz J.R., Vesely D.L., Finley C.L., Skolnick K.A., Fabri P.J., et al. Atrial natriuretic peptide gene expression in the rat gastrointestinal tract. Biochem Biophys Res Commun 1994, 202:562-570.
129. Gower W.R., Salhab K.F., Foulis W.L., Pillai N., Bund J.R., Vesely D.L., et al. Regulation of atrial natriuretic peptide gene expression in gastric antrum by fasting. Am J Physiol 2000, 278:R770-R780.
130. Gower W.R., San Miguel GI, Carter GM, Hassan I, Farese RV, Vesely DL Atrial natriuretic prohormone gene expression in cardiac and extracardiac tissues of diabetic Goto-Kakizaki rats. Mol Cell Biochem 2003, 252:263-271.
131. Gower W.R., Vesely B.A., Alli A.A., Vesely D.L. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′,5′-cyclic monophosphate. Int J Gastrointestinal Cancer 2005, 36:77-87.
132. Gower W.R., Vesely D.L. The gastrointestinal natriuretic peptide system. Trends Comp Biochem Physiol 2000, 6:125-138.
133. Grammer R.T., Fukumi H., Inagami T., Misono K.S. Rat atrial natriuretic factor. Purification and vasorelaxant activity. Biochem Biophys Res Commun 1983, 116:696-703.
134. Green M., Ruiz O.S., Kear F., Arruda J.A. Dual effect of cyclic GMP on renal brush border Na-H antiporter. Proc Soc Exp Biol Med 1991, 198:846-851.
135. Greenberg B.D., Bencen G.H., Seilhamer J.J., Lewicki J.A., Fiddes J.C. Nucleotide sequence of the gene encoding human ANF precursor. Nature 1984, 312:656-658.
136. Greenberg R.N., Hill M., Crytzer J., Krause W.J., Eber S.L., Hamra F.K., et al. Comparison of effects of uroguanylin, guanylin, and Escherichia coli heat-stable entertoxin STa in mouse intestine and kidney: evidence that uroguanylin is an intestinal natriuretic hormone. J Invest Med 1997, 45:276-282.
137. Greenwald J.E., Needleman P., Wilkins M.R., Schreiner G.F. Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. Am J Physiol 1991, 260:F602-F607.
138. Grepin C., Dagino L., Robitaille L., Haberstroh L., Antakly T., Nemer M. A hormone-encoding gene identifies a pathway for cardiac but not skeletal muscle gene transcription. Mol Cell Biol 1994, 14:3115-3129.
139. 2. J Clin Invest 1992, 89:1411-1417.
140. Gunning M.E., Brenner B.M. Natriuretic peptides and the kidney: current concepts. Kidney Int 1992, 42(Suppl. 38):S127-S133.
141. Habibullah A.A., Villarreal D., Freeman R.H., Dietz J.R., Vesely D.L., Simmons J.C. Atrial natriuretic peptide fragments in dogs with experimental heart failure. Clin Exp Pharmacol Physiol 1995, 22:130-135.
142. Hamra F.K., Forte L.R., Eber S.L., Pidhorodeckyj N.V., Krause W.J., Freeman R.H., et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 1993, 90:10464-10468.
143. Harma F., Hagiwara H., Inoue A., Yamaguchi A., Yokose S., Furuya M., et al. cGMP produced in response to ANP and CNP regulates proliferation and differentiation of osteoblastic cells. Am J Physiol 1996, 270:C1311-C1318.
144. Hammond T.G., Haramati A., Knox F.G. Synthetic atrial natriuretic factor decreases renal tubular phosphate reabsorption in rats. Am J Physiol 1985, 249:F315-F318.
145. Harris P.J., Thomas D., Morgan T.O. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987, 326:697-698.
146. Harthshorne H. Water versus hydrotherapy 1847, Lloyd P. Smith Press, Philadelphia.
147. Harvey W. Exercitatio de motu cordis et sanguinis animalibus. Leake CD [trans], Francofurti guilielem fitzeri, 1628 1928, Charles C. Thomas, Springfield, IL.
148. Hayashida H., Miyata T. Sequence similarity between epidermal growth factor precursor and atrial natriuretic factor precursor. FEBS Lett 1985, 185:125-128.
149. Henrich W.L. Southwestern Internal Medicine Conference: renal sodium excretion and atrial natriuretic factor. Am J Med Sci 1986, 291:199-208.
150. Henry J.P., Gauer O.H., Reeves J.L. Evidence of the atrial location of receptors influencing urine flow. Circ Res 1956, 4:85-90.
151. Henry J.P., Pearce J.W. The possible role of cardiac atrial stretch receptors in the induction of changes in urine flow. J Physiol 1956, 131:572-585.
152. Hirata Y., Tomita M., Takada S., Yoshimi H. Vascular receptor binding activities and cyclic GMP responses by synthetic human and rat atrial natriuretic peptides (ANP) and receptor down-regulation by ANP. Biochem Biophys Res Commun 1985, 128:538-546.
153. Hock R., Anderson R.J. Prevention of drug-induced nephrotoxicity in the intensive care unit. J Crit Care 1995, 10:33-43.
154. Hou S.H., Bushinsky D.A., Wish J.B., Cohen J.J., Harrington J.T. Hospital acquired renal insufficiency: a prospective study. Am J Med 1983, 74:243-248.
155. Huet M., Benchimol S., Berlinguet J.C., Castonguay Y., Cantin M. Cytochimie ultrastructurale des cardiocytes de l'oreillette humaine. IV. Digestion des granules specifiques par less proteases. J Microsc 1974, 21:147-158.
156. Huet M., Cantin M. Ultrastructural cytochemistry of atrial muscle cells. II. Characterization of the protein content of specific granules. Lab Invest 1974, 30:525-532.
157. Humphreys M.H. Gamma-MSH, sodium metabolism, and salt sensitive hypertension. Am J Physiol 2004, 286:R417-R430.
158. Humphreys M.H., Lin S.Y. Peptide hormones and the control of sodium excretion. Hypertension 1988, 11:397-410.
159. Hunt P.J., Richards A.M., Espiner E.A., Nicholls M.E., Yandle T.G. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994, 78:1428-1435.
160. Hunter E.F.M., Kelly P.A., Prowse C., Woods F.J., Lowry P.J. Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest 1998, 58:205-216.
161. Igaki T., Itoh H., Suga S., Hama N., Ogawa Y., Komatsu Y., et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int 1996, 49(Suppl. 55):S144-S147.
162. Itoh H., Pratt R.E., Dzau V.J. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990, 86:1690-1697.
163. Itoh H., Pratt R.E., Ohno M., Dzau V.J. Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells. Hypertension 1992, 19:758-761.
164. Jamieson J.D., Palade G.E. Specific granules in atrial muscle cell. J Cell Biol 1964, 23:151-162.
165. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer Statistics, 2009. Ca Cancer J Clin 2009, 59:225-249.
166. Jensen K.T., Eiskjaer H., Carstens J., Pedersen E.B. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci 1999, 96:5-15.
167. 2 release. Am J Physiol 2004, 287:R1101-R1109.
168. John S.W.M., Krege J.H., Oliver P.M., Hagaman J.R., Hodgkin J.B., Pang S.C., et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995, 267:679-681.
169. Johnson A., Lermioglu F., Garg U.C., Morgan-Boyd R., Hassid A. A novel biological effect of atrial natriuretic hormone: inhibition of mesangial cell mitogenesis. Biochem Biophys Res Commun 1988, 152:893-897.
170. Jougasaki M., Burnett J.C. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000, 66:855-872.
171. Kangawa K., Fukuda A., Kubota I., Hayashi Y., Matsuo H. Identification in rat atrial tissue of multiple forms of natriuretic polypeptides of about 3,000 daltons. Biochem Biophys Res Commun 1984, 121:585-591.
172. Kangawa K., Fukuda A., Matsuo H. Purification and complete amino acid sequence of rat atrial natriuretic polypeptides of 5,000 daltons. Biochem Biophys Res Commun 1984, 119:933-940.
173. Kangawa K., Fukuda A., Matsuo H. Structural identification of beta- and gamma-human atrial natriuretic polypeptides (β- and γ-ANP). Nature 1985, 313:397-400.
174. Kangawa K., Matsuo H. Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP). Biochem Biophys Res Commun 1984, 118:131-139.
175. Kangawa K., Tawaragi Y., Oikawa S., Mizuno A., Sakuragawa Y., Nakazato M., et al. Identification rat gamma atrial natriuretic polypeptide and characterization of the cDNA encoding its precursor. Nature 1984, 312:152-155.
176. Karla P.R., Anker S.D., Struthers A.D., Coats A.J.S. The role of C-natriuretic peptide in cardiovascular medicine. Eur Heart J 2001, 22:997-1007.
177. Kalra P.R., Clague J.R., Bolger A.P., Anker S.D., Poole-Wilson P.A., Struthers A.D., et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003, 107:571-573.
178. Karlberg L., Norlen B.J., Ojteg G., Wolgast M. Impaired medullary circulation in postischemic acute renal failure. Acta Physiol Scand 1983, 118:11-17.
179. Kasahara M., Mukoyama M., Sugawara A., Makino H., Suganami T., Ogawa Y., et al. Ameliorated glomerular injury in mice over expressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000, 11:1691-1701.
180. Kaufman R.P., Anner H., Kobzik L., Valeri C.R., Shepro D., Hechtman H.B. Vasodilator prostaglandins (PG) prevent renal damage after ischemia. Ann Surg 1987, 205:195-198.
181. Keeler R. Atrial natriuretic factor has a direct, prostaglandin-independent action on kidneys. Can J Physiol Pharmacol 1982, 60:1078-1082.
182. Kelley M.J., Johnson B.E. Molecular biology of lung cancer. The molecular basis of cancer 2001, 260-287. W.B. Saunders Company, Philadelphia. 2nd ed. J. Mendelsohn, P.M. Howley, M.A. Israel, L.A. Liotta (Eds.).
183. Kennedy B.P., Marsden J.J., Flynn T.G., DeBold A.J., Davies P.L. Isolation and nucleotide sequence of a cloned cardionatrin cDNA. Biochem Biophys Res Commun 1984, 122:1076-1082.
184. Kentsch M., Drummer C., Gerzer R., Muller-Esch G. Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure. Eur J Clin Invest 1995, 25:281-283.
185. Kikuchi M., Fujimoto S., Fukae H., Kinoshita H., Kita T., Nakazato M., et al. Role of uroguanylin, a peptide with natriuretic activity, in rats with experimental nephrotic syndrome. J Am Soc Nephrol 2005, 16(2):392-397.
186. Kinoshita H., Fujimoto S., Fukae H., Yokota N., Hisanaga S., Nakazato M., et al. Plasma and urine levels of uroguanylin, a new natriuretic peptide, in nephrotic syndrome. Nephron 1999, 81:160-164.
187. Kinoshita H., Nakazato M., Yamaguchi H., Matsukura S., Fujimoto S., Eto T. Increased plasma guanylin levels in patients with impaired renal function. Clin Nephrol 1997, 47:28-32.
188. Kisch B. Studies in comparative electron microscopy of the heart. II. Guinea pig and rat. Exp Med Surg 1955, 13:404-428.
189. Kitamura K., Kangawa K., Kawamoto M., Ichiki Y., Nakamura S., Matsuo H., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560.
190. Kitamura K., Kangawa K., Matsuo H., Eto T. Adrenomedullin: implications for hypertension research. Drugs 1995, 49:485-495.
191. Kleinert H.D., Maack T., Atlas S.A., Januszewicz A., Sealey J.E., Laragh J.H. Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. Hypertension 1984, 6(Suppl. I):I143-I147.
192. Kohse K.P., Feifel K., Mayer-Wehrstein R. Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol 1993, 40:83-90.
193. Kojima S., Inoue I., Hirata Y., Kimura G., Saito F., Kawano Y., et al. Plasma concentrations of immunoreactive-atrial natriuretic polypeptide in patients on hemodialysis. Nephron 1987, 46:45-48.
194. Koller K.J., Goeddel D.V. Molecular biology of natriuretic peptides and their receptors. Circulation 1992, 86:1081-1088.
195. Kudo T., Baird A. Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor. Nature 1984, 312:756-757.
196. Kurnik B.R., Allgren R.L., Genter F.C., Solomon R.J., Bates E.R., Weisberg L.S. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998, 31:674-680.
197. Kurtz A., Della Bruna R., Pfeilschifter J., Taugner R., Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by cGMP-mediated process. Proc Natl Acad Sci USA 1986, 83:4769-4773.
198. Ladenson P.W., Bloch K.D., Seidman J.G. Modulation of atrial natriuretic factor by thyroid hormone: messenger ribonucleic acid and peptide levels in hypothyroid, euthyroid, and hyperthyroid rat atria and ventricles. Endocrinology 1988, 123:652-657.
199. Lainchbury J., Richards A.M., Nicholls M.G. Brain natriuretic peptide in heart failure. Atrial natriuretic peptides 1997, 151-158. Research Signpost, Trivandrum, India. D.L. Vesely (Ed.).
200. Lang C.C., Choy A.M., Henderson I.S., Coutie W.J., Struthers A.D. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci 1992, 82:127-131.
201. La Pointe M.C., Deschepper C.F., Wu J., Gardner D.G. Extracellular calcium regulates expression of the gene for atrial natriuretic factor. Hypertension 1990, 15:20-28.
202. Lazure C., Seidah N.G., Chretien M., Thibault G., Garcia R., Cantin M., et al. Atrial pronatriodilatin: a precursor for natriuretic factor and cardiodilatin. FEBS Lett 1984, 172:80-86.
203. Lee S.J., Kim S.Z., Cui X., Kim S.H., Lee K.S., Chung Y.J., et al. C-type natriuretic peptide inhibits ANP secretion and atrial dynamics in perfused atria: NPR-B-cGMP signaling. Am Heart J 2000, 278:H208-H221.
204. Lennane R.J., Peart W.S., Carey R.M., Shaw J. A comparison on natriuresis after oral and intravenous sodium loading in sodium-depleted rabbits: evidence for a gastrointestinal or portal monitor of sodium intake. Clin Sci Mol Med 1975, 49:433-436.
205. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med 1998, 339:321-328.
206. Levinsky N.G., Lalone R.C. Mechanism of sodium diuresis after saline infusion in the dog. J Clin Invest 1963, 42:1261-1268.
207. Lewis J., Salem M.M., Chertow G.M., Weisberg L.S., McGrew F., Marbury T.C., et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000, 36:767-774.
208. Lieberthal W., Sheridan A.M., Valeri C.R. Protective effect of atrial natriuretic factor and mannitol following renal ischemia. Am J Physiol 1990, 258:F1266-F1272.
209. Linden R.J., Sreeharan N. Humoral nature of the urine response to stimulation of atrial receptors. Q J Exp Physiol 1981, 66:431-438.
210. Lisy O., Jougasaki M., Heublein D.M., Schirger J.A., Chen H.H., Wennberg P.W., et al. Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999, 56:502-508.
211. Lorenz J.N., Nieman M., Sabo J., Sanford L.P., Hawkins J.A., Elitsur N., et al. Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load. J Clin Invest 2003, 112:1244-1254.
212. Luchner A., Stevens T.L., Borgeson D.D., Redfield M., Wei C.M., Porter J.G., et al. Differential atrial and ventricular expression of myocardial BNP during evaluation of heart failure. Am J Physiol 1998, 274:H1684-H1689.
213. Lydtin H., Hamilton W.F. Effect of acute changes in left atrial pressure on urine flow in unanesthetized dogs. Am J Physiol 1964, 207:503-536.
214. Maack T., Marion D.N., Camargo M.J., Kleinert H.D., Laragh J.H., Vaughan E.D., et al. Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. Am J Med 1984, 77:1069-1075.
215. Maack T., Suzuki M., Almedida F.A., Nussenzveig D., Scarborough R.W., McEnroe G.A., et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987, 238:675-678.
216. Maki M., Takayanagi R., Misono K.S., Pandy K.N., Tibbetts C., Inagami T. Structure of rat atrial natriuretic factor precursor deduced for cDNA sequence. Nature 1984, 309:722-724.
217. Marcus L.S., Hart D., Packer M., Yushak M., Medina N., Danziger R.S., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusions in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94:3184-3189.
218. Marie J.P., Guillemont H., Hatt P.Y. Le degree de granulation des cardiocytes auriculaires. Etude planimetrique au cours de differents apports d'eau et de sodium chez le rat. Pathol Biol 1976, 24:549-554.
219. Marin-Grez M., Fleming J.T., Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986, 324:473-476.
220. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990, 258:F1401-F1408.
221. Marttila M., Puhakka J., Luodonpaa M., Vuolteenaho O., Ganten L., Ruskoaho H. Augmentation of BNP gene expression in atria by pressure overload in transgenic rats harboring human renin and angiotensinogen genes. Blood Press 1999, 8:308-316.
222. Marx U.C., Klodt J., Meyer M., Gerlach H., Rosch P., Forsmann W.G., et al. One peptide, two topologies: structure and interconversion dynamics of human uroguanylin isomers. J Pept Res 1998, 2:229-240.
223. Mattingly M.T., Brandt R.R., Heublein D.M., Wei C.M., Nir A., Burnett J.C. Presence of C-type natriuretic peptide in human kidney and urine. Kidney Int 1994, 46:744-747.
224. McCubrey J.A., Steelman L.S., Chappell W.H., Abrams S.L., Wong E.W.T., Chang F., et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773:1263-1284.
225. McCubrey J.A., Milella M., Tafuri A., Martelli A.M., Lunghi P., Bonati A., et al. Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008, 9:614-630.
226. McMurray J., Seidenlin P.H., Howey J.E.A., Balfour D.J., Struthers A.D. The effect of atrial natriuretic factor on urinary albumin and beta-2-microglobulin excretion in man. Hypertension 1988, 6:783-786.
227. McMurray R.W., Vesely D.L. Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism 1989, 38:1231-1237.
228. Melander O., Frandsen E., Groop L., Hulthen U.L. Plasma proANP 1-30 reflects salt sensitivity in subjects with hereditary for hypertension. Hypertension 2002, 39:996-999.
229. Merkouris R.W., Miller F.C., Catanzarite V., Rigg L.A., Quirk J.G., Vesely D.L. Increase in the plasma levels of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor in normal pregnancy. Am J Obstet Gynecol 1990, 162:859-864.
230. Merkouris R.W., Miller F.C., Catanzarite V., Quirk J.G., Rigg L.A., Vesely D.L. The N-terminal and C-terminal portions of the atrial natriuretic factor prohormone increase during preeclampsia. Am J Obstet Gynecol 1991, 164:1197-1202.
231. Meyer M., Richter R., Forssmann W.G. Urodilatin a natriuretic peptide with clinical implications. Eur J Med Res 1998, 3:103-110.
232. Meyer M., Pfarr E., Schirmer G., Uberbacher H.J., Schope K., Bohm E., et al. Therapeutic use of the natriuretic peptide ularitide in acute renal failure. Ren Fail 1999, 21:85-100.
233. Mills R.M., LeJemtel T.H., Horton D.P., Liang C., Lang R., Silver M.A., et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999, 34:155-162.
234. Molitoris B.A., Meyer C., Dahl R., Geerdes A. Mechanism of ischemia-enhanced aminoglycoside binding and uptake by proximal tubule cells. Am J Physiol 1993, 264:F907-F916.
235. Morgan D.A., Peuler J.D., Koepke J.P., Mark A.L., DiBona G.F. Renal sympathetic nerves attenuate the natriuretic effects of atrial peptide. J Lab Clin Med 1989, 114:538-544.
236. Morrissey E.C., Wilner K.D., Barager R.R., Ward D.M., Ziegler M.G. Atrial natriuretic factor in renal failure and posthemodialytic postural hypotension. Am J Kidney Dis 1988, 12:510-515.
237. 1 in the dog with norepinephrine-induced acute renal failure. Invest Radiol 1975, 10:284-299.
238. Moss N.G., Fellner R.C., Qian X., Yu S.J., Li Z., Nakazato M., et al. Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide. Endocrinology 2008, 149:4486-4498.
239. Moss N.G., Riguera D.A., Solinga R.M., Kessler M.M., Zimmer D.P., Arendshorst W.J., et al. The natriuretic peptide uroguanylin elicits physiologic actions through 2 distinct topoisomers. Hypertension 2009, 53:867-876.
240. Nakao K., Ogawa Y., Suga S., Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I. Natriuretic peptides. J Hypertens 1992, 10:907-912.
241. Nakamoto M., Shapiro J.I., Shanley P.F., Chan L., Schrier R.W. In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J Clin Invest 1987, 80:698-705.
242. Nakayama K., Ohkubo H., Hirose T., Inayama S., Nakanishi S. mRNA sequence for human cardiodilatin-atrial natriuretic factor precursor and regulation of precursor mRNA in rat atria. Nature 1984, 310:699-701.
243. Nasser A., Dietz J.R., Siddique M., Patel H., Khan N., Antwi E.K., et al. Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am J Cardiol 2001, 88:23-29.
244. Nemer M., Chamberland M., Sirois D., Argentin J., Drouin R.A., Dixon R.A., et al. Gene structure of human cardiac hormone precursor, pronatriodilatin. Nature 1984, 312:654-656.
245. Neumayer H.H., Blossei N., Seherr-Thohs U., Wagner K. Amelioration of postischaemic acute renal failure in conscious dogs by human atrial natriuretic peptide. Nephrol Dial Transplant 1990, 5:32-38.
246. Ngo L., Bissett J.K., Winters C.J., Vesely D.L. Plasma prohormone atrial natriuretic peptides 1-98 and 31-67 increase with supraventricular and ventricular arrhytmias. Am J Med Sci 1990, 300:71-77.
247. Ngo L., Wyeth R.P., Bissett J.K., Hester W.L., Newton M.T., Sallman A.L., et al. Prohormone atrial natriuretic peptides 1-30, and 99-126 increase in proportion to right ventricular pacing rate. Am Heart J 1989, 118:893-900.
248. Nishikimi T., Mori Y., Kobayashi N., Tadokoro K., Wang X., Akimoto K., et al. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension 2002, 39:1077-1082.
249. Ogawa E., Saito Y., Kuwahara K., Harada M., Miyamoto Y., Hamana I., et al. Fibronectin signaling stimulates BNP gene transcription by inhibiting neuron-restrictive silencer element-dependent repression. Cardiovasc Res 2002, 53:451-459.
250. Ohlstein E.H., Berkowitz B.A. Cyclic guanosine monophosphate mediates vascular relaxation induced by atrial natriuretic factor. Hypertension 1985, 7:306-310.
251. Oikawa S., Imai M., Inuzuka C., Tawaragi Y., Nakazato H., Matsuo H. Structure of dog and rabbit precursors of atrial natriuretic polypeptides deduced from nucleotide sequence of cloned cDNA. Biochem Biophys Res Commun 1985, 132:892-899.
252. Oikawa S., Imai M., Ueno A., Tanaka S., Noguchi T., Nakazato H., et al. Cloning and sequence analysis of cDNA encoding a precursor for human atrial natriuretic peptide. Nature 1984, 309:724-726.
253. Orias R., McCann S.M. Natriuresis induced by alpha and beta melanocyte stimulating hormones in rats. Endocrinology 1972, 90:700-706.
254. Ortola F.V., Ballermann B.J., Brenner B.M. Endogenous ANP augments fractional excretion of Pi, Ca, and Na in rats with reduced renal mass. Am J Physiol 1988, 255:F1091-F1097.
255. Palmer B.F., Alpern R.J. Pathogenesis of edema formation in the nephrotic syndrome. Kidney Int 1997, 59:521-527.
256. Palmer P.A., Friedl F.E., Giordano A.T., Vesely D.L. Alteration of environmental salinity modulates atrial natriuretic peptides' concentrations in heart, and hemolymph of the oyster, Crassostrea virginica. Comp Biochem Physiol 1994, 108A:589-597.
257. Parkes D.G. Cardiovascular actions of adrenomedullin in conscious sheep. Am J Physiol 1995, 268:H2574-H2578.
258. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
259. Paul R.V., Kirk K.A., Navar L.G. Renal autoregulation and pressure natriuresis during ANF-induced diuresis. Am J Physiol 1987, 253:F424-F431.
260. Payvar F., DeFranco D., Firestone G., Edgar B., Wrange O., O'Kret S., et al. Sequence specific binding of glucocorticoid receptor to MMTV DNA at sites within and upstream of the transcribed region. Cell 1983, 35:381-392.
261. Pedram A., Razandi M., Hu R.M., Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem 1997, 272:17097-17103.
262. Peters J.P. Body water: the exchange of fluids in man 1935, Charles C Thomas, Springfield, IL.
263. Pettersson A., Hedner J., Hedner T. Renal interaction between sympathetic activity and ANP in rats with chronic heart failure. Acta Physiol Scand 1989, 135:487-492.
264. Pettersson A., Hedner J., Ricksten S.E., Towle A.C., Hedner T. Acute volume expansion as a physiological stimulus for the release of atrial natriuretic peptides in the rat. Life Sci 1986, 38:1127-1133.
265. Pevahouse J.B., Flanigan W.J., Winters C.J., Vesely D.L. Normalization of elevated circulating N-terminal and C-terminal atrial natriuretic factor prohormone concentrations by renal transplantation. Transplantation 1992, 53:1375-1377.
266. Pikkarainen S., Tokola H., Majalahti-Palviainen T., Kerkela R., Hautala N., Bahalla S.S., et al. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J Biol Chem 2003, 278:23807-23816.
267. Pitchumoni C.S. Pancreatic disease. Internal Medicine 1998, 2233-2247. Mosby, St. Louis, MO. J.H. Stein (Ed.).
268. Poche R. Electronenmikroskopische untersuchuwgen des liopfuscin im herzmuskel des menschen. Zbl Allg Path Anat 1957, 96:395.
269. Poche R. Submikroskopische beitrage zur pathologie der herzmuskelzelle bei phosphorvergiftung. Hypertrophie, atrophie und kaliummangel. Virchows Arch 1958, 331:165-248.
270. +-ATPase. Renal Physiol 1983, 6:295-299.
271. Potthast R., Ehler E., Sheving L.A., Sindic A., Schlatter E., Kuhn M. High salt intake increases uroguanylin expression in mouse kidney. Endocrinology 2001, 142:3087-3097.
272. Poulos J.E., Gower W.R., Fontanet H.L., Kalmus G.W., Vesely D.L. Cirrhosis with ascites: increased atrial natriuretic peptide gene expression in rat ventricle. Gastroenterology 1995, 108:1496-1503.
273. Poulos J.E., Gower W.R., Friedl F.E., Vesely D.L. Atrial natriuretic peptide gene expression within invertebratic hearts. Gen Comp Endocrinol 1995, 100:61-68.
274. Poulos J.E., Gower W.R., Sullebarger J.T., Fontanet H.L., Vesely D.L. Congestive heart failure: increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res 1996, 32:909-919.
275. Proudfoot N. The end of the message. Nature 1982, 298:516-517.
276. Proudfoot N.T., Brownlee G.G. 3′ non-coding region sequences in eukaryotic messenger RNA. Nature 1976, 263:211-214.
277. Qian X., Moss N.G., Fellner R.C., Goy M.F. Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules. Endocrinology 2008, 149:4499-4509.
278. Rahman S.N., Kim G.E., Mathew A.S., Goldberg C.A., Allgren R., Schrier R.W., et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994, 45:1731-1738.
279. Raine A.E., Anderson J.V., Bloom S.R., Morris P.J. Plasma atrial natriuretic factor and graft function in renal transplant recipients. Transplantation 1989, 48:796-800.
280. Rambotti M.G., Giambanco I., Spreca A. Detection of guanylate cyclases A and B stimulated by natriuretic peptides in gastrointestinal tract of rat. Histochem J 1996, 29:117-126.
281. Ramirez G., Saba S.R., Dietz J.R., Vesely D.L. Immunocytochemical localization of proANF1-30, proANF 31-67, and atrial natriuretic factor in the kidney. Kidney Int 1992, 41:334-341.
282. Rapoport R.M. Cyclic guanosine monophosphate inhibition of contraction may be mediated through inhibition of phosphatidylinositol hydrolysis in rat aorta. Circ Res 1986, 58:407-410.
283. Rapoport R.M., Ginsburg R., Waldman S.A., Murad F. Effects of atriopeptins on relaxation and cyclic GMP levels in human coronary artery in vitro. Eur J Pharmacol 1986, 124:193-196.
284. Rascher W., Tulassay T., Lang R.E. Atrial natriuretic peptide in plasma of volume-overloaded children with chronic renal failure. Lancet 1985, 2:303-305.
285. Rashed H.M., Su H., Patel T.B. Atrial natriuretic peptide inhibits growth of hepatoblastoma (HEP G2) cells by means of activation of clearance receptors. Hepatology 1993, 17:677-684.
286. Richards A.M., Lainchbury J.G., Nicholls M.G., Cameron A.V., Yandle T.G. Dendroaspis natriuretic peptide: endogenous or dubious?. Lancet 2002, 359:5-6.
287. Riordan J.R. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol 1993, 55:609-630.
288. Ritter D., Chao J., Needleman P., Tetens E., Greenwald J.E. Localization, synthetic regulation, and biology of renal atriopeptin-like prohormone. Am J Physiol 1992, 263:F503-F509.
289. Roberts P.J., Der C.J. Targeting the RAF-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
290. Rosenzweig A., Seidman C.E. Atrial natriuretic factor and related peptide hormones. Annu Rev Biochem 1991, 60:229-255.
291. Rubattu S., Gilberti R., Ganten U., Volpe M. A differential brain atrial natriuretic peptide expression co-segregates with occurrence of early strokes in the stroke prone phenotype of spontaneously hypertensive rat. J Hypertens 1999, 17:1849-1852.
292. Rubattu S., Lee-Kirsch M.A., DePaolis P., Giliberti R., Gigante B., Lombardi A., et al. Altered structure, regulation, and function of the gene encoding the atrial natriuretic peptide in stroke prone spontaneously hypertensive rat. Cir Res 1999, 85:900-905.
293. Rubattu S., Ridker P., Stampfer M.J., Volpe M., Henekens C.H., Lindpaintner K. The gene encoding atrial natriuretic peptide and the risk of human stroke. Circulation 1999, 100:1722-1726.
294. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992, 44:479-602.
295. Ruskoaho H., Leskinen H., Magga J., Tashinen P., Mantymaa P., Vuolteenaho O., et al. Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide, and angiotensin II. J Mol Med 1997, 75:876-885.
296. Ryu H., Cho K.W., Kim S.H., Kim S.Z., Oh S.H., Hwang Y.H., et al. Frog lymph heart synthesizes and stores immune reactivate atrial natriuretic peptide. Gen Comp Endocrinol 1992, 87:171-177.
297. Saba S.R., Ramirez G., Vesely D.L. Immunocytochemical localization of ProANF 1-30, ProANF 31-67, atrial natriuretic factor and urodilatin in the human kidney. Am J Nephrol 1993, 13:85-93.
298. Saba S.R., Garces A.H., Clark L.C., Gower W.R., Vesely D.L. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005, 53:989-995.
299. Saba S.R., Vesely D.L. Cardiac natriuretic peptides: hormones with anti-cancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers. Histol Hitopathol 2006, 21:775-783.
300. Sagnella G.A., Saggar-Malik A.K., Buckley M.G., Markandu N.D., Eastwood J.B., MacGregor G.A. Association between atrial natriuretic peptide and cyclic GMP in hypertension and in chronic renal failure. Clin Chem Acta 1998, 275:9-18.
301. Samson W.K. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 1999, 61:363-389.
302. Samson W.K. Proadrenomedullin-derived peptides. Front Neuroendocrinol 1998, 19:100-117.
303. Sands J.M., Neylan J.F., Olson R.A., O'Brien D.P., Whelchel J.D., Mitch W.E. Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation. J Am Soc Nephrol 1991, 1:1081-1086.
304. Santos-Neto M.S., Carvalho A.F., Monteiro H.S., Forte L.R., Fonteles M.C. Interaction of atrial natriuretic peptide, urodilatin, guanylin and uroguanylin in the isolated perfused rat kidney. Regul Pept 2006, 136:14-22.
305. Sato K., Hirata Y., Imai T., Iwashita M., Mariuo F. Characterization of immunoreactive adrenomedullin in human plasma and urine. Life Sci 1995, 57:189-194.
306. Sato K., Imai T., Iwashina M., Marumo F., Hirata Y. Secretion of adrenomedullin by renal tubular cell lines. Nephron 1998, 78:9-14.
307. Saxenhofer H., Gnadinger M.P., Weidmann P., Shaw S., Schohn D., Hess C., et al. Plasma levels and dialysance of atrial natriuretic peptide in terminal renal failure. Kidney Int 1987, 32:554-561.
308. Schafferhans K., Heidbreder E., Grimm D., Heidland A. Norepinephrine-induced acute renal failure: beneficial effects of atrial natriuretic factor. Nephron 1986, 44:240-244.
309. Schermuly R.T., Weissmann N., Enke B., Ghofrani H.A., Forssmann W.G., Grimminger F., et al. Urodilatin, a natriuretic peptide stimulating guanylate cyclase, and the phosphodiesterase five inhibitor dipyridamole attenuate experimental pulmonary hypertension. Am J Respir Cell Mol Biol 2001, 25:219-225.
310. Schirger J.A., Heublein D.M., Chen H.H., Lisy O., Jougasaki M., Wennberg P.W., et al. Presence of Dendroaspis natriuretic peptide-like immunoreactivity in human plasma and its increase during human heart failure. Mayo Clin Proc 1999, 74:126-130.
311. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
312. Schnermann J., Marin-Grez M., Briggs J.P. Filtration pressure response to infusion of atrial natriuretic peptides. Pflugers Arch 1986, 406:237-239.
313. Scholl F.A., Dumesic P.A., Khavan P.A. Effects of active MEK 1 expression in vivo. Cancer Lett 2005, 230:1-8.
314. Schramm L., Heidbreder E., Schaar J., Lopau K., Zimmermann J., Gotz R., et al. Toxic acute renal failure in the rat: effects of diltiazem and urodilatin on renal function. Nephron 1994, 68:454-461.
315. Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R., Forssmann W.G. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988, 66:752-759.
316. Schweitz H., Vigne P., Moinier D., Frelin C., Lazdunski M. A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis augusticeps). J Biol Chem 1992, 267:13928-13932.
317. Scivoletto R., Carcalho M.H.C. Cardionatrin causes vasodilation in vitro which is not dependent on the presence of endothelial cells. Eur J Pharmacol 1984, 101:143-145.
318. Scriven T.A., Burnett J.C. Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985, 72:892-897.
319. Sebolt-Leopold J.S. Advances in the development of cancer therapeutics directed against the Ras mitogen-activated protein kinase pathway. Clin Can Res 2008, 14:3651-3656.
320. Sebolt-Leopold J.S., Herrera R. Targeting the mtogen-activated protein kinase casecade to treat cancer. Nature Rev Cancer 2004, 4:937-947.
321. Seidman C., Bloch K.D., Klein K.A., Smith J.A., Seidman J.G. Nucleotide sequences of the human and mouse atrial natriuretic factor genes. Science 1984, 226:1206-1209.
322. Shaw S.G., Weidmann P., Hodler J., Zimmermann A., Paternostro A. Atrial natriuretic peptide protects against ischemic renal failure in the rat. J Clin Invest 1987, 80:1232-1237.
323. Shaw S.G., Weidmann P., Zimmermann A. Urodilatin not nitroprusside, combined with dopamine reverses ischemic acute renal failure. Kidney Int 1992, 42:1153-1159.
324. Shin S.J., Lee Y.J., Tan M.S., Hsieh T.J., Tsai J.H. Increased atrial natriuretic peptide mRNA expression in the kidney of diabetic rats. Kidney Int 1997, 51:1100-1105.
325. Sindic A., Velic A., Basoglu C., Hirsch J.R., Edemir B., Kuhn M., et al. Uroguanylin and guanylin regulate transport of mouse cortical collecting duct independent of guanylate cyclase C. Kidney Int 2005, 68:1008-1017.
326. Sindic A., Schlatter E. Mechanisms of action or uroguanylin and guanylin and their role in salt handling. Nephrol Dial Transplant 2006, 21:3007-3012.
327. Soejima H., Grekin R.J., Briggs J.P., Schnermann J. Renal response of anesthetized rats to low-dose infusion of atrial natriuretic peptide. Am J Physiol 1988, 255:R449-R455.
328. Sosa R.E., Volpe M., Marion D.N., Atlas S.A., Laragh J.H., Vaughn E.D., et al. Relationship between renal hemodynamic and natriuretic effects of atrial natriuretic factor. Am J Physiol 1986, 250:F520-F524.
329. Sothern R.B., Vesely D.L., Kanabrocki E.L., Bremner F.W., Third J.L.A.C., Boles M.A., et al. Blood pressure and atrial natriuretic peptides correlate throughout the day. Am Heart J 1995, 129:907-916.
330. Sothern R.B., Vesely D.L., Kanabrocki E.L., Hermida R.C., Bremner F.W., Third J.L.A.C., et al. Temporal (circadian) and functional relationship between atrial natriuretic peptides and blood pressure. Chronobiol Int 1995, 12:106-120.
331. Steinhelper M.E., Cochrane K.L., Field L.J. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990, 16:301-307.
332. Sudoh T., Kangawa K., Minamino W., Matsuo H. A new natriuretic peptide in porcine brain. Nature 1988, 332:78-81.
333. Sudoh T., Minamino N., Kangawa K., Matsuo H. C-type natriuretic peptide (CNP): a new member of the natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990, 168:863-870.
334. Sugawara A., Nakao K., Sakamoto M., Morii N., Yamada T., Itoh H., et al. Plasma concentration of atrial natriuretic polypeptide in essential hypertension. Lancet 1985, 2:1426-1427.
335. Sun Y., Eichelbaum E.J., Skelton W.P., Lenz A., Regales N., Wang H., et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009, 29:971-975.
336. Sun Y., Eichelbaum E.J., Lenz A., Skelton W.P., Wang H., Vesely D.L. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009, 29:1889-1893.
337. Sun Y., Eichelbaum E.J., Wang H., Vesely D.L. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006, 26:3217-3222.
338. Sun Y., Eichelbaum E.J., Wang H., Vesely D.L. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006, 26:4143-4148.
339. Sun Y., Eichelbaum E.J., Wang H., Vesely D.L. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007, 27:1387-1392.
340. Sun Y., Eichelbaum E.J., Wang H., Vesely D.L. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007, 27:3813-3818.
341. Sun Y., Eichelbaum E.J., Wang H., Vesely D.L. Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol 2007, 3:113-120.
342. Suzuki E., Hirata Y., Hayakawa H., Omata M., Kojima M., Kangawa K., et al. Evidence for C-type natriuretic peptide production in the rat kidney. Biochem Biophys Res Commun 1993, 192:532-538.
343. Tamura N., Ogawa Y., Chusho H., Nakamura K., Nakao K., Suda M., et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci USA 2000, 97:4239-4244.
344. Tateyama H., Hino J., Minamino N., Kangawa K., Ogihara T., Matsuo H. Characterization of immunoreactive brain natriuretic peptide in human cardiac atrium. Biochem Biophys Res Commun 1990, 166:1080-1087.
345. Thuerauf D.J., Hanford D.S., Glembotski C.C. Regulation of rat brain natriuretic peptide transcription. Potential role for GATA-related transcription factors in myocardial gene expression. J Biol Chem 1994, 269:17772-17775.
346. Tokura T., Kinoshita H., Fujimoto S., Kitamura K., Eto T. Plasma levels of proadrenomedullin N-terminal 20 peptide and adrenomedullin in patients undergoing hemodialysis. Nephron Clin Pract 2003, 95:C67-C72.
347. Totsune K., Mackenzie H.S., Totsune H., Troy J.L., Lytton J., Brenner B.M. Upregulation of atrial natriuretic peptide gene expression in remnant kidney of rats with reduced renal mass. J Am Soc Nephrol 1998, 9:1613-1617.
348. Totsune K., Takahashi, Murakami O., Satoh F., Sone M., Mouri T. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci 1994, 87:319-322.
349. Trippodo N.C., MacPhee A.A., Cole F.E., Blakesley H.L. Partial chemical characterization of a natriuretic substance in rat atrial heart tissue. Proc Soc Exp Biol Med 1982, 170:502-508.
350. Tsuchimochi H., Yazaki Y., Ohno H., Takanashi R., Takaku F. Ventricular expression of atrial natriuretic peptide. Lancet 1987, 2:336-337.
351. Valentin J.P., Gardner D.G., Wiedemann E., Humphreys M.H. Modulation of endothelin effects on blood pressure and hematocrit by atrial natriuretic peptide. Hypertension 1991, 17:864-869.
352. Valentin J.P., Ying W.Z., Couser W.G., Humphreys M.H. Extra renal resistance to atrial natriuretic peptide in rats with experimental nephrotic syndrome. Am J Physiol 1998, 274:F556-F563.
353. Vaporciyan A.A., Kies M., Stevens C., Komaki R., Roth J.A. Cancer of the lung. Cancer medicine 2003, 1385-1445. Decker Inc., Hamilton, Ontario, BC. 6th ed. D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, R.C. Bast, T.S. Gansler, J.R. Holland, E. Frei (Eds.).
354. Vari R.C., Freeman R.H., Davis J.O., Villarreal D., Verburg K.M. Effect of synthetic atrial natriuretic factor on aldosterone secretion in the rat. Am J Physiol 1986, 251:R48-R52.
355. Vesely B.A., Alii A.A., Song S., Gower W.R., Sanchez-Ramos J., Vesely D.L. Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 2005, 35:700-710.
356. Vesely B.A., Eichelbaum E.J., Alli A.A., Sun Y., Gower W.R., Vesely D.L. Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 2006, 36:810-819.
357. Vesely B.A., Eichelbaum E.J., Alii A.A., Sun Y., Gower W.R., Vesely D.L. Four cardiac hormones cause cell death in 81% of human ovarian adenocarcinoma cells. Cancer Therapy 2007, 5:97-104.
358. Vesely B.A., Eichelbaum E.J., Alii A.A., Sun Y., Gower W.R., Vesely D.L. Four cardiac hormones cause cell death of melanoma cells and inhibit their DNA synthesis. Am J Med Sci 2007, 334:342-349.
359. Vesely B.A., Eichelbaum E.J., Alii A.A., Sun Y., Gower W.R., Vesely D.L. Four cardiac hormones eliminate 4-fold more human glioblastoma cells than green mamba snake peptide. Cancer Lett 2007, 254:94-101.
360. Vesely B.A., Fitz S.R., Gower W.R., Vesely D.L. Vessel dilator: most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 2006, 232:226-231.
361. Vesely B.A., McAfee Q., Gower W.R., Vesely D.L. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003, 33:998-1005.
362. Vesely B.A., Song S., Sanchez-Ramos J., Fitz S.R., Solivan S.M., Gower W.R., et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005, 35:60-69.
363. Vesely B.A., Alli A., Song S., Sanchez-Ramos J., Fitz S.R., Gower W.R., et al. Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells. Cardiology 2006, 105:226-233.
364. Vesely B.A., Song S., Sanchez-Ramos J., Fitz S.R., Alli A., Solivan S.M., et al. Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005, 35:388-398.
365. Vesely D.L. Aprotinin blocks the binding of pro atrial natriuretic peptides 1-30, 31-67, and 99-126 to human placental membranes. Am J Obstet Gynecol 1991, 165:567-573.
366. Vesely D.L. Atrial natriuretic hormones 1992, Prentice Hall, Englewood Cliffs, NJ.
367. Vesely D.L. Atrial natriuretic peptides within invertebrates and plants. Trends Comp Biochem Physiol 1998, 4:89-103.
368. Vesely D.L. Atrial natriuretic peptides in pathophysiological diseases. Cardiovasc Res 2001, 51:647-658.
369. Vesely D.L. Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153-159.
370. Vesely D.L. Natriuretic peptides and acute renal failure. Am J Physiol 2003, 285:F167-F177.
371. Vesely D.L., Arnold W.C., Winters C.J., Sallman A.L., Rico D.M. Increased circulating concentration of atrial natriuretic factor in persons with pheochromocytomas. Clin Exp Hypertens [A] 1989, 11:353-369.
372. Vesely D.L., Arnold W.C., Winters C.J., Sallman A.L., Rico D.M. Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab 1990, 71:1138-1146.
373. Vesely D.L., Bayliss J.M., Sallman A.L. Human prepro atrial natriuretic factors 26-55 56-92 and 104-123 increase renal guanylate cyclase activity. Biochem Biophys Res Commun 1987, 143:186-193.
374. Vesely D.L., Blankenship M., Douglass M.A., McCormick M.T., Rodriguez-Paz G., Schocken D.D. Atrial natriuretic peptide increases adrenomedullin in the circulation of healthy humans. Life Sci 1996, 59:243-254.
375. Vesely D.L., Chiou S., Douglass M.A., McCormick M.T., Rodriguez-Paz G., Schocken D.D. Kaliuretic peptide and long acting natriuretic peptide as well as atrial natriuretic factor inhibit aldosterone secretion. J Endocrinol 1995, 146:373-380.
376. Vesely D.L., Chiou S., Douglass M.A., McCormick M.T., Rodriguez-Paz G., Schocken D.D. Atrial natriuretic peptides negatively and positively modulate circulating endothelin in humans. Metabolism 1996, 45:315-319.
377. Vesely D.L., Clark L.C., Garces A.H., McAfee Q.W., Soto J., Gower W.R. Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004, 34:674-682.
378. Vesely D.L., Cornett L.E., McCleod S.L., Nash A.A., Norris J.S. Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides 1990, 11:193-197.
379. Vesely D.L., Dietz J.R., Parks J.R., Antwi E.A., Overton R.M., McCormick M.T., et al. Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J 1999, 138:625-632.
380. Vesely D.L., Dietz J.R., Parks J.R., Baig M., McCormick M.T., Cintron G., et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998, 98:323-329.
381. Vesely D.L., Douglass M.A., Dietz J.R., Giordano A.T., McCormick M.T., Rodriguez-Paz G., et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994, 78:1128-1134.
382. Vesely D.L., Douglass M.A., Dietz J.R., Gower W.R., McCormick M.T., Rodriguez-Paz G., et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994, 90:1129-1140.
383. Vesely D.L., Eichelbaum E.J., Sun Y., Alli A.A., Vesely B.A., Luther S.L., et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007, 21:445-452.
384. Vesely D.L., Giordano A.T. Food intake and body positional change alter the circadian rhythm of atrial natriuretic peptides excretion into human urine. Chronobiol Int 1991, 8:373-384.
385. Vesely D.L., Giordano A.T. Atrial natriuretic factor-like peptide and its prohormone within single cell organisms. Peptides 1992, 13:177-182.
386. Vesely D.L., Giordano A.T. The most primitive heart in the animal kingdom contains the atrial natriuretic peptide hormonal system. Comp Biochem Physiol 1992, 101C:325-329.
387. Vesely D.L., Gower W.R., Giordano A.T. Atrial natriuretic peptides throughout the plant kingdom: enhancement of solute flow by peptides from the N-terminus of the atrial natriuretic factor prohormone. Am J Physiol 1993, 265:E465-E477.
388. Vesely D.L., Hadley M.E. Calcium requirements for melanophore-stimulating hormone action on melanophores. Science 1971, 173:923-925.
389. Vesely D.L., Norris J.S., Walters J.M., Jespersen R.R., Baeyens D.A. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987, 148:1540-1548.
390. Vesely D.L., Norsk P., Gower W.R., Chiou S., Epstein M. Release of kaliuretic peptide during immersion-induced central hypervolemia in healthy humans. Proc Soc Exp Biol Med 1995, 209:20-26.
391. Vesely D.L., Norsk P., Winters C.J., Rico D.M., Sallman A.L., Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989, 192:230-235.
392. Vesely D.L., Overton R.M., Blankenship M., McCormick M.T., Schocken D.D. Atrial natriuretic peptide increases urodilatin in the circulation. Am J Nephrol 1998, 18:204-213.
393. Vesely D.L., Palmer P.A., Giordano A.T. Atrial natriuretic factor prohormone peptides are present in a variety of tissues. Peptides 1992, 13:165-170.
394. 2 microglobulin. Metabolism 2000, 49:1592-1597.
395. 2 microglobulin in congestive heart failure patients. J Cardiac Failure 2001, 7:55-63.
396. Vesely D.L., Preston R., Gower W.R., Chiou S., Epstein M. Increased release of kaliuretic peptide during immersion-induced central hypervolemia in cirrhotic humans. Am J Nephrol 1996, 16:128-137.
397. Vesely D.L., Sallman A.L., Bayliss J.M. Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol Biochem 1992, 15:23-32.
398. Vesely D.L. San Miguel GI, Hassan I, Schocken DD. Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of corticotropin releasing hormone, corticotropin and cortisol. J Clin Endocrinol Metab 2001, 86:4244-4249.
399. Vesely D.L., Vesely B.A., Eichelbaum E.J., Sun Y., Alli A.A., Gower W.R. Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 2007, 21:973-978.
400. Vesely D.L., Winters C.J., Sallman A.L. Prohormone atrial natriuretic peptides 1-30 and 31-67 increase in hyperthyroidism and decrease in hypothyroidism. Am J Med Sci 1989, 297:209-215.
401. Vesely M.D., Gower W.R., Perez-Lamboy G.I., Overton R.M., Graddy L., Vesely D.L. Evidence for an atrial natriuretic peptide-like gene in plants. Exp Biol Med 2001, 226:61-65.
402. Vesely M.D., Vesely D.L. Environmental upregulation of atrial natriuretic peptide gene in the living fossil, Limulus polyphemus. Biochem Biophys Res Commun 1999, 254:751-756.
403. Villarreal D., Freeman R.H., Reams G.P. Natriuretic peptides and salt sensitivity: endocrine cardiorenal integration in heart failure. Congest Heart Fail 2002, 8:29-36.
404. Villarreal D., Freeman R.H., Taraben A., Reams G.P. Modulation of renin secretion by atrial natriuretic factor prohormone fragment 31-67. Am J Med Sci 1999, 318:330-335.
405. Villarreal D., Reams G.P., Taraben A., Freeman R.H. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999, 221:166-170.
406. Vlasuk G., Miller J., Beneen G., Lewicki J. Structure and analysis of the bovine atrial natriuretic peptide precursor gene. Biochem Biophys Res Commun 1986, 136:396-403.
407. Vuolteenaho O., Arjama O., Vakkuri O., Madsniemi T., Nikkila L., Kangas J., et al. Atrial natriuretic peptide (ANP) in rat gastrointestinal tract. FEBS Lett 1988, 233:79-82.
408. Vuolteenaho O., Leskinen H., Magga J., Taskinen P., Mantymaa P., Leppaluoto J., et al. Regulation of atrial natriuretic peptide synthesis and secretion. Atrial natriuretic peptides 1997, 39-52. Research Signpost, Trivandrum, India. D.L. Vesely (Ed.).
409. Waldman S.A., Rapoport R.M., Murad F. Atrial natriuretic factor selectively activates particulate guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984, 259:14332-14334.
410. Walshe J.J., Venuto R.C. Acute oliguric renal failure induced by indomethacin: possible mechanism. Ann Intern Med 1979, 91:47-49.
411. Walter T., Stepan H., Pankow K., Becker M., Schultheiss H.P., Sein W.E. Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. J Biol Chem 2004, 385:179-184.
412. Wang T., Kawabata M., Haneda M., Takabatake T. Effects of uroguanylin, an intestinal natriuretic peptide, on ubuloglomerular feedback. Hypertens Res 2003, 26:557-582.
413. Weidmann P., Hasler L., Gnadinger M.P., Lang R.E., Uehlinger D.E., Shaw S., et al. Blood levels and renal effects of atrial natriuretic peptide in normal man. J Clin Invest 1986, 77:734-742.
414. 2] in glycerol-induced acute renal failure in rats. Clin Sci Mol Med 1978, 55:505-507.
415. Westenfelder C., Birch F.M., Baranowski R.L., Rosenfeld M.J., Shiozawa D.K., Kablitz C. Atrial natriuretic factor and salt adaptation in the teleost fish Gila atraria. Am J Physiol 1988, 255:F1281-F1286.
416. Weston M.W., Cintron G.B., Giordano A.T., Vesely D.L. Normalization of circulating atrial natriuretic peptides in cardiac transplant recipients. Am Heart J 1994, 127:129-142.
417. Wilkins M.R., Wood J.A., Adu D., Lote C.J., Kendall M.J., Michael J. Change in plasma immunoreactive atrial natriuretic peptide during sequential ultrafiltration and haemodialysis. Clin Sci 1986, 71:157-160.
418. Williamson J.R., Holmberg S.W., Chang K., Marvel J., Sutera S.P., Needleman P. Mechanisms underlying atriopeptin-induced increases in hematocrit and vascular permeation in rats. Circ Res 1989, 64:890-899.
419. Winquist R.J., Faison E.P., Waldman S.A., Schwartz K., Murad F., Rapoport R.M. Atrial natriuretic factor elicits an endothelium independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. Proc Natl Acad Sci USA 1984, 81:7661-7664.
420. Winters C.J., Sallman A.L., Baker B.J., Meadows J., Rico D.M., Vesely D.L. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989, 80:438-449.
421. Winters C.J., Sallman A.L., Meadows J., Rico D.M., Vesely D.L. Two new hormones: prohormone atrial natriuretic peptides 1-30 and 31-67 circulate in man. Biochem Biophys Res Commun 1988, 150:231-236.
422. Winters C.J., Vesely D.L. Change in plasma immunoreactive N-terminus, C-terminus, and 4000 dalton mid portion of atrial natriuretic factor prohormone with hemodialysis. Nephron 1991, 58:17-22.
423. Woolf A.S., Mansell M.A., Hoffbrand B.I., Cohen S.L., Moult P.J. The effect of low dose intravenous 99-126 atrial natriuretic factor infusion in patients with chronic renal failure. Postgrad Med J 1989, 65:362-366.
424. Wolff R.A., Abbruzzese J.L., Evans D.B. Neoplasms of the exocrine pancreas. Cancer medicine 2000, 1436-1474. BC Decker Inc, London. J.F. Holland, E. Frei (Eds.).
425. Wu J., Harrison J.K., Dent P., Lynch K.R., Weber M.J., Sturgill T.W. Identification and characterization of a new mammalian mitogen-activated protein kinase kinase MKK-2. Mol Cell Biol 1993, 13:4539-4548.
426. Yamanaka M., Greenberg B., Johnson L., Seilhamer J., Brewer M., Friedemann T., et al. Cloning and sequence analysis of the cDNA for the rat atrial natriuretic factor precursor. Nature 1984, 309:719-722.
427. Yang Q., Gower W.R., Li C., Chen P., Vesely D.L. Atrial natriuretic-like peptide and its prohormone within Metasequoia. Proc Soc Exp Biol Med 1999, 221:188-192.
428. Yokota N., Bruneau B.G., Fernandez B.E., Kuroski de Bold M.L., Piazza L.A., Eid H., et al. Dissociation of cardiac hypertrophy, myosin heavy chain isoform expression, and natriuretic peptide production in DOCA-salt rats. Am J Hypertens 1995, 8:301-310.
429. Yonemaru M., Ishii K., Murad F., Raffin T.A. Atriopeptin-induced increases in endothelial permeability are associated with elevated cGMP levels. Am J Physiol 1992, 263:L363-L369.
430. Yoshida K., Yamagata T., Tomura Y., Suzuki-Kusaba M., Yoshida M., Hisa H., et al. Effects of c-type natriuretic peptide on vasoconstriction in dogs. Eur J Pharmacol 1997, 338:131-134.
431. Yu S.M., Hung L.M., Lin C.C. CGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 1997, 95:1269-1277.
432. Yuge S., Inoue K., Hyodo S., Takei Y. A novel guanylin family (guanylin, uroguanylin, and renoguanylin) in eels: possible osmoregulartory hormones in intestine and kidney. J Biol Chem 2003, 278:22726-22733.
433. Zeidel M.L. Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. Annu Rev Physiol 1990, 52:747-759.
434. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995, 22:121-124.
435. Zeidel M.L., Kikeri D., Silva P., Burrowes M., Brenner B.M. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest 1988, 82:1067-1074.
436. Zhang P.L., Mackenzie H.S., Troy K.L., Brenner B.M. Effects of natriuretic peptide receptor inhibition on remnant kidney function in rats. Kidney Int 1994, 46:414-420.
437. Zietse R., Schalekamp M.A. Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome. Kidney Int 1988, 34:717-724.
438. Zimmerman R.S., Gharib H., Zimmerman D., Heublein D., Burnett J.C. Atrial natriuretic peptide in hypothyroidism. J Clin Endocrinol Metab 1987, 64:353-355.
439. Zimmerman R.S., Trippodo N.C., MacPhee A.A., Martinez A.Z., Barbee R.W. High-dose atrial natriuretic factor enhances albumin escape from the systemic but not the pulmonary circulation. Circ Res 1990, 67:461-468.
440. Zivin R.A., Condra J.H., Dixon R., Seidah N.G., Chreitien M., Nemer M., et al. Molecular cloning and characterization of DNA sequences encoding rat and human ANF. Proc Natl Acad Sci USA 1984, 81:6325-6329.
441. Zuidema G.D., Clarke N.P., Reeves J.L., Gauer O.H., Henry J.P. Influence of moderate changes in blood volume on urine flow. Am J Physiol 1956, 186:89-92.
442. Ying Sun, Ehrentraud J. Eichelbaum, Anne Lenz, Hai Wang, David L. Vesely. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. European Journal of Clinical Investigation, 2010;40(5):408-13.